Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Interventions
Combination Product: AURN001 + Y-27632, Placebo
Drug · Other
Lead sponsor
Aurion Biotech
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Mesa, Arizona • Little Rock, Arkansas • Fort Collins, Colorado + 9 more
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT04520321
Conditions
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions
TTHX1114(NM141), Vehicle (placebo)
Drug · Other
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more
Conditions
Corneal Edema, Corneal Endothelial Dysfunction
Interventions
AURN001, Corneal Endothelial Cells, Y27632
Combination Product · Biological · Drug
Lead sponsor
Aurion Biotech
Industry
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty

NCT00744796
Conditions
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Interventions
DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
Procedure · Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
Interventions
EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose
Biological
Lead sponsor
Emmecell
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Greater Los Angeles, California • San Diego, California • Miami, Florida + 5 more
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina